142 related articles for article (PubMed ID: 11347960)
21. 3,4-Diarylpiperidines as potent renin inhibitors.
Lacombe P; Arbour M; Aspiotis R; Cauchon E; Chen A; Dubé D; Falgueyret JP; Fournier PA; Gallant M; Grimm E; Han Y; Juteau H; Liu S; Mellon C; Ramtohul Y; Simard D; St-Jacques R; Tsui GC
Bioorg Med Chem Lett; 2012 Mar; 22(5):1953-7. PubMed ID: 22325946
[TBL] [Abstract][Full Text] [Related]
22. Structural modification of the P2' position of 2,7-dialkyl-substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamides: the discovery of aliskiren, a potent nonpeptide human renin inhibitor active after once daily dosing in marmosets.
Maibaum J; Stutz S; Göschke R; Rigollier P; Yamaguchi Y; Cumin F; Rahuel J; Baum HP; Cohen NC; Schnell CR; Fuhrer W; Gruetter MG; Schilling W; Wood JM
J Med Chem; 2007 Oct; 50(20):4832-44. PubMed ID: 17824680
[TBL] [Abstract][Full Text] [Related]
23. Ro 42-5892 is a potent orally active renin inhibitor in primates.
Fischli W; Clozel JP; el Amrani K; Wostl W; Neidhart W; Stadler H; Branca Q
Hypertension; 1991 Jul; 18(1):22-31. PubMed ID: 1830563
[TBL] [Abstract][Full Text] [Related]
24. A novel class of oral direct renin inhibitors: highly potent 3,5-disubstituted piperidines bearing a tricyclic p3-p1 pharmacophore.
Ostermann N; Ruedisser S; Ehrhardt C; Breitenstein W; Marzinzik A; Jacoby E; Vangrevelinghe E; Ottl J; Klumpp M; Hartwieg JC; Cumin F; Hassiepen U; Trappe J; Sedrani R; Geisse S; Gerhartz B; Richert P; Francotte E; Wagner T; Krömer M; Kosaka T; Webb RL; Rigel DF; Maibaum J; Baeschlin DK
J Med Chem; 2013 Mar; 56(6):2196-206. PubMed ID: 23360239
[TBL] [Abstract][Full Text] [Related]
25. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats.
Pilz B; Shagdarsuren E; Wellner M; Fiebeler A; Dechend R; Gratze P; Meiners S; Feldman DL; Webb RL; Garrelds IM; Jan Danser AH; Luft FC; Müller DN
Hypertension; 2005 Sep; 46(3):569-76. PubMed ID: 16103264
[TBL] [Abstract][Full Text] [Related]
26. Renin inhibitors. Dipeptide analogues of angiotensinogen utilizing a dihydroxyethylene transition-state mimic at the scissile bond to impart greater inhibitory potency.
Luly JR; BaMaung N; Soderquist J; Fung AK; Stein H; Kleinert HD; Marcotte PA; Egan DA; Bopp B; Merits I
J Med Chem; 1988 Dec; 31(12):2264-76. PubMed ID: 3143009
[TBL] [Abstract][Full Text] [Related]
27. Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.
Chen A; Aspiotis R; Campeau LC; Cauchon E; Chefson A; Ducharme Y; Falgueyret JP; Gagné S; Han Y; Houle R; Laliberté S; Larouche G; Lévesque JF; McKay D; Percival D
Bioorg Med Chem Lett; 2011 Dec; 21(24):7399-404. PubMed ID: 22071301
[TBL] [Abstract][Full Text] [Related]
28. Control of arterial pressure and renal function during chronic renin inhibition.
Hall JE; Mizelle HL
J Hypertens; 1990 Apr; 8(4):351-9. PubMed ID: 2160492
[TBL] [Abstract][Full Text] [Related]
29. Optimization of orally bioavailable alkyl amine renin inhibitors.
Xu Z; Cacatian S; Yuan J; Simpson RD; Jia L; Zhao W; Tice CM; Flaherty PT; Guo J; Ishchenko A; Singh SB; Wu Z; McKeever BM; Scott BB; Bukhtiyarov Y; Berbaum J; Mason J; Panemangalore R; Cappiello MG; Bentley R; Doe CP; Harrison RK; McGeehan GM; Dillard LW; Baldwin JJ; Claremon DA
Bioorg Med Chem Lett; 2010 Jan; 20(2):694-9. PubMed ID: 19959358
[TBL] [Abstract][Full Text] [Related]
30. Comparative Effects of Direct Renin Inhibitor and Angiotensin Receptor Blocker on Albuminuria in Hypertensive Patients with Type 2 Diabetes. A Randomized Controlled Trial.
Uzu T; Araki SI; Kashiwagi A; Haneda M; Koya D; Yokoyama H; Kida Y; Ikebuchi M; Nakamura T; Nishimura M; Takahara N; Obata T; Omichi N; Sakamoto K; Shingu R; Taki H; Nagai Y; Tokuda H; Kitada M; Misawa M; Nishiyama A; Kobori H; Maegawa H;
PLoS One; 2016; 11(12):e0164936. PubMed ID: 28033332
[TBL] [Abstract][Full Text] [Related]
31. The human renin infused rat: use as an in vivo model for the biological evaluation of human renin inhibitors.
Bolger G; Vigeant JC; Liard F; Simoneau B; Thibeault D; Pilote L; Lamarre D; Jung G; Anderson P; Jaramillo J
Can J Physiol Pharmacol; 1999 Nov; 77(11):886-95. PubMed ID: 10593662
[TBL] [Abstract][Full Text] [Related]
32. A novel renal hypertensive guinea pig model for comparing different inhibitors of the renin-angiotensin system.
Duan J; Jaramillo J; Jung GL; McLeod AL; Fernandes BH
J Pharmacol Toxicol Methods; 1996 Apr; 35(2):83-9. PubMed ID: 8729434
[TBL] [Abstract][Full Text] [Related]
33. Will renin inhibitors influence decision-making in antihypertensive therapy?
Haber E
J Hypertens Suppl; 1985 Nov; 3(2):S71-80. PubMed ID: 3003303
[TBL] [Abstract][Full Text] [Related]
34. Substituted piperidines--highly potent renin inhibitors due to induced fit adaptation of the active site.
Vieira E; Binggeli A; Breu V; Bur D; Fischli W; Güller R; Hirth G; Märki HP; Müller M; Oefner C; Scalone M; Stadler H; Wilhelm M; Wostl W
Bioorg Med Chem Lett; 1999 May; 9(10):1397-402. PubMed ID: 10360744
[TBL] [Abstract][Full Text] [Related]
35. Haemodynamic effects of acute and chronic renin inhibition in marmosets.
Wood JM; Baum HP; Forgiarini P; Gulati N; Jobber RA; Neisius D; Hofbauer KG
J Hypertens Suppl; 1989 Apr; 7(2):S37-42. PubMed ID: 2547039
[TBL] [Abstract][Full Text] [Related]
36. Renal and systemic effects of the renin inhibitor remikiren in patients with essential hypertension.
van Paassen P; de Zeeuw D; de Jong PE
J Cardiovasc Pharmacol; 1995 Jul; 26(1):39-45. PubMed ID: 7564363
[TBL] [Abstract][Full Text] [Related]
37. Effects of AT1 receptor blockade on blood pressure and the renin-angiotensin system in spontaneously hypertensive rats of the stroke prone strain.
Wagner J; Drab M; Bohlender J; Amann K; Wienen W; Ganten D
Clin Exp Hypertens; 1998 Feb; 20(2):205-21. PubMed ID: 9533614
[TBL] [Abstract][Full Text] [Related]
38. Renin inhibition--benefit beyond hypertension control.
Kher V
J Assoc Physicians India; 2009 Jul; 57():518-20, 525. PubMed ID: 20329413
[TBL] [Abstract][Full Text] [Related]
39. Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin.
Rahuel J; Rasetti V; Maibaum J; Rüeger H; Göschke R; Cohen NC; Stutz S; Cumin F; Fuhrer W; Wood JM; Grütter MG
Chem Biol; 2000 Jul; 7(7):493-504. PubMed ID: 10903938
[TBL] [Abstract][Full Text] [Related]
40. Novel renin inhibitors containing (2S,3S,5S)-2-amino-1-cyclohexyl-6-methyl-3,5-heptanediol fragment as a transition-state mimic at the P1-P1' cleavage site.
Yamada Y; Ando K; Ikemoto Y; Tada H; Shirakawa E; Inagaki E; Shibata S; Nakamura I; Hayashi Y; Ikegami K; Uchida I
Chem Pharm Bull (Tokyo); 1997 Oct; 45(10):1631-41. PubMed ID: 9353891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
